ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Science Translational Medicine | March 13, 2019 | Volume: 11 | Issue: 483 | Pages: No page available
10.1126/scitranslmed.aaq1238
| PMID 30867319
Suppression of ZEB1 through miR-200 expression or HDAC inhibition with mocetinostat sensitizes resistant KRAS mutant lung cancers to MEK inhibition.